NAMIBIA MEDICINES REGULATORY COUNCIL



MINISTRY OF HEALTH AND SOCIAL SERVICES

APPLICATION FOR REGISTRATION OF A MEDICINE¹ Module 1: Administrative Information Application Form

This application form will be included in the Namibia Common Technical Document – Module 1 Administrative Information.

The application form is to be used for an application for registration of a medicinal product for human or veterinary use submitted to the Namibia Medicines Regulatory Council.

Usually a separate application form for each strength and pharmaceutical dosage form is required.

	APPLICATION NUMBER		
L			

a) Particulars of the Applicant/Prospective holder of the certificate of registration (PHCR)

Name:	
Business address:	
Postal address:	

¹ Read together with the definition in Act 13 of 2003 as amended

Talanhanana	
Telephone no:	
Fax no:	
E-mail address:	
Site/Applicant Master File Number	"
Pharmacist responsible/authorised	d to communicate with NA Regulatory Authority
Name:	
Business address:	
Telephone no:	
Fax no:	
E-mail address:	
Particulars of the medicine Product	
Particulars of the medicine Product Category:	
Product Category:	
Product Category: Proprietary name:	
Product Category: Proprietary name: Pharmacological classification:	
Product Category: Proprietary name: Pharmacological classification: Dosage form:	
Product Category: Proprietary name: Pharmacological classification: Dosage form:	
Product Category: Proprietary name: Pharmacological classification: Dosage form: 2Approved name(s):	dicine:
Product Category: Proprietary name: Pharmacological classification: Dosage form: 2Approved name(s): Strength(s) per dosage unit:	dicine:
Product Category: Proprietary name: Pharmacological classification: Dosage form: 2Approved name(s): Strength(s) per dosage unit: Descriptive name of Biological med	
Product Category: Proprietary name: Pharmacological classification: Dosage form: ² Approved name(s): Strength(s) per dosage unit: Descriptive name of Biological med Route of administration: Country of origin (country in which development was carried out):	h the original
Product Category: Proprietary name: Pharmacological classification: Dosage form: ² Approved name(s): Strength(s) per dosage unit: Descriptive name of Biological med Route of administration: Country of origin (country in which	h the original

 $^{^2}$ Only one name per API in the product should be given: The International Non-proprietary Name (INN) accompanied by its salt or hydrate form (if relevant), or chemical description of the API(s)

³ If more than one site is involved, clearly identify the site for *each* stage.

Site Master File reference number(s):	
Date of submission	
Licence number:	
Date of issue:	
Primary Packer(s):	
Physical address of site(s):	
Site Master File reference number(s):	
Date of submission	
Licence number:	
Date of issue:	
Secondary Packer(s):	
Physical address of site(s):	
Site Master File reference number(s):	
Date of submission:	
Licence number:	
Date of issue:	
Finished product release control (FPRC)(s):
Physical address of site(s):	
Site Master File reference number(s):	
Date of submission:	
Licence number:	
Date of issue:	
Finished product release responsibility (FF	PRR)(s):
Physical address of site(s):	
Site Master File reference number(s):	

Date of submission			
Licence number:			
Date of issue:			
	es of the latest GMP certificate for ce(s) have been included in section.	manufacturer(s) and packer(s) or a cop 1.7.3 (delete items not applicable).	y of th
Declaration and signature			
	ar medicine, and that all existing o	the Annexes and Modules hereto, are cor lata which are relevant to the quality, sa	
☐ It is hereby confirmed that fees ho	ave been paid according to current	legislation, and proof is attached in Anne.	x 1.2.2.
Signature of Pharmacist [Section a) a			
Name in block letters	Date of a	pplication	
 Designation			
Sesignation	Date of C	urrent amendment (Post-registration only)
l) Type of application NEW APPLICATION		cy, and the review procedure using a chec	
Type of application NEW APPLICATION Indicate the type of medicine, the type			
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X):	e of data included as proof of effica	cy, and the review procedure using a chec	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine:	e of data included as proof of effica	cy, and the review procedure using a chec Data as proof of efficacy:	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical	e of data included as proof of efficac NCE Multisource	Data as proof of efficacy: Pre-clinical	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical Biological	e of data included as proof of efficac NCE Multisource Biosimilar	Data as proof of efficacy: Pre-clinical Clinical	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical Biological Veterinary Medicine:	e of data included as proof of efficace NCE Multisource Biosimilar Line Extension	Data as proof of efficacy: Pre-clinical Clinical Biostudy	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical Biological Veterinary Medicine: Pharmaceutical Pharmaceutical	e of data included as proof of efficace NCE Multisource Biosimilar Line Extension	Data as proof of efficacy: Pre-clinical Clinical Biostudy	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical Biological Veterinary Medicine: Pharmaceutical Biological	e of data included as proof of efficace NCE Multisource Biosimilar Line Extension	Data as proof of efficacy: Pre-clinical Clinical Biostudy	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical Biological Veterinary Medicine: Pharmaceutical Biological Review Procedure:	NCE Multisource Biosimilar Line Extension Call-up	Data as proof of efficacy: Pre-clinical Clinical Biostudy Other	
Type of application NEW APPLICATION Indicate the type of medicine, the type ✓) or a cross (X): Human Medicine: Pharmaceutical Biological Veterinary Medicine: Pharmaceutical Biological Review Procedure:	NCE Multisource Biosimilar Line Extension Call-up	Data as proof of efficacy: Pre-clinical Clinical Biostudy Other	

Date of application(s) (yyyy-mm-dd):	

AMENDMENT/VARIATION

Indicate the type of amendment/variation using a check mark (\checkmark) or a cross (X):

Inspectorate	Response to pre-registration recommendation:	
Pharmaceutical and Analytical	Pharmaceutical & Analytical	
Clinical	Clinical	
Proprietary Name	Proprietary Name	

e) Qualified person for Pharmacovigilance

Name:	
Business address:	
24 Hour Telephone no:	
Fax no:	
E-mail address:	
(Attach CV – Annex 1.2.2.5)	

f) Amendment history (Post-registration only)

Date of letter of amendment application	Summarised details of amendment (include Type and Category)	Date of Regulatory Authority response